The Estrogen Pathway: Estrogen Receptor-α, Progesterone Receptor, and Estrogen Receptor-β Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens

Winston Tan, Stephen Boorjian, Pooja Advani, Sara Farmer, Christine Lohse, John Cheville, Eugene D Kwon, Bradley Leibovich

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The estrogen pathway has been implicated in bladder cancer growth and progression. We evaluated the expression and intensity of estrogen receptor (ER)-α, ER-β, and progesterone receptor in patients with urothelial cell carcinoma who were treated with cystectomy. Progesterone receptor expression was negative in all cases. ER-α expression was noted in 12 of 318 patients, and ER-β expression was noted in all patients. Marked ER-β intensity was associated with decreased lymph node metastasis, smaller tumor size, preoperative Bacillus Calmettee - Guérin, and less nonorgan-confined disease, suggesting a potential prognostic role of ER-β in urothelial cell carcinoma. Objective: Bladder cancer has the sixth highest incidence in the United States. Treatment of metastatic bladder cancer is difficult, and mortality is certain. There are certain pathways in cancer growth and progression that are important in bladder cancer development. Recently, the estrogen pathway has been found to be a potential target for therapy. Methods: We identified 410 patients treated with radical cystectomy for urothelial cell carcinoma between 1990 and 1994. We obtained representative paraffin-embedded tissue blocks for 336 (82.0%) of these cases and evaluated the expression and intensity of estrogen receptor (ER)-α, ER-β, and progesterone receptor by immunohistochemistry. Results: Among the 12 ER-α-positive cases, median tumor ER-α expression was 10% (range, 10%-50%). In contrast to ER-α, all cases were ER-β-positive. Median tumor ER-β expression was 90% (range, 20%-100%). Nearly all cases had ER-β expression of ≥ 90% (175 [55.9%] with 90% and 103 [32.9%] with 100%). However, the intensity of ER-β staining varied from focal to moderate to marked in 64 (20.5%), 167 (53.4%), and 82 (26.2%) cases, respectively. Progesterone receptor expression was noted to be negative in all cases. Conclusions: ER-β is highly expressed in bladder cancer. Prospective validation of these data might further elucidate the utility of ER-β as a marker for prognosis or possible target for therapy.

Original languageEnglish (US)
Pages (from-to)476-484
Number of pages9
JournalClinical Genitourinary Cancer
Volume13
Issue number5
DOIs
StatePublished - Oct 1 2015

Fingerprint

Cystectomy
Progesterone Receptors
Estrogen Receptors
Estrogens
Carcinoma
Urinary Bladder Neoplasms
Neoplasms
Growth

Keywords

  • Estrogen receptor
  • Muscle-invasive bladder cancer
  • Prognosis
  • Urothelial cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

The Estrogen Pathway : Estrogen Receptor-α, Progesterone Receptor, and Estrogen Receptor-β Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens. / Tan, Winston; Boorjian, Stephen; Advani, Pooja; Farmer, Sara; Lohse, Christine; Cheville, John; Kwon, Eugene D; Leibovich, Bradley.

In: Clinical Genitourinary Cancer, Vol. 13, No. 5, 01.10.2015, p. 476-484.

Research output: Contribution to journalArticle

Tan, Winston ; Boorjian, Stephen ; Advani, Pooja ; Farmer, Sara ; Lohse, Christine ; Cheville, John ; Kwon, Eugene D ; Leibovich, Bradley. / The Estrogen Pathway : Estrogen Receptor-α, Progesterone Receptor, and Estrogen Receptor-β Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens. In: Clinical Genitourinary Cancer. 2015 ; Vol. 13, No. 5. pp. 476-484.
@article{2fb813a517e44d3890f3501e3ad6974a,
title = "The Estrogen Pathway: Estrogen Receptor-α, Progesterone Receptor, and Estrogen Receptor-β Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens",
abstract = "The estrogen pathway has been implicated in bladder cancer growth and progression. We evaluated the expression and intensity of estrogen receptor (ER)-α, ER-β, and progesterone receptor in patients with urothelial cell carcinoma who were treated with cystectomy. Progesterone receptor expression was negative in all cases. ER-α expression was noted in 12 of 318 patients, and ER-β expression was noted in all patients. Marked ER-β intensity was associated with decreased lymph node metastasis, smaller tumor size, preoperative Bacillus Calmettee - Gu{\'e}rin, and less nonorgan-confined disease, suggesting a potential prognostic role of ER-β in urothelial cell carcinoma. Objective: Bladder cancer has the sixth highest incidence in the United States. Treatment of metastatic bladder cancer is difficult, and mortality is certain. There are certain pathways in cancer growth and progression that are important in bladder cancer development. Recently, the estrogen pathway has been found to be a potential target for therapy. Methods: We identified 410 patients treated with radical cystectomy for urothelial cell carcinoma between 1990 and 1994. We obtained representative paraffin-embedded tissue blocks for 336 (82.0{\%}) of these cases and evaluated the expression and intensity of estrogen receptor (ER)-α, ER-β, and progesterone receptor by immunohistochemistry. Results: Among the 12 ER-α-positive cases, median tumor ER-α expression was 10{\%} (range, 10{\%}-50{\%}). In contrast to ER-α, all cases were ER-β-positive. Median tumor ER-β expression was 90{\%} (range, 20{\%}-100{\%}). Nearly all cases had ER-β expression of ≥ 90{\%} (175 [55.9{\%}] with 90{\%} and 103 [32.9{\%}] with 100{\%}). However, the intensity of ER-β staining varied from focal to moderate to marked in 64 (20.5{\%}), 167 (53.4{\%}), and 82 (26.2{\%}) cases, respectively. Progesterone receptor expression was noted to be negative in all cases. Conclusions: ER-β is highly expressed in bladder cancer. Prospective validation of these data might further elucidate the utility of ER-β as a marker for prognosis or possible target for therapy.",
keywords = "Estrogen receptor, Muscle-invasive bladder cancer, Prognosis, Urothelial cell carcinoma",
author = "Winston Tan and Stephen Boorjian and Pooja Advani and Sara Farmer and Christine Lohse and John Cheville and Kwon, {Eugene D} and Bradley Leibovich",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.clgc.2015.04.001",
language = "English (US)",
volume = "13",
pages = "476--484",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - The Estrogen Pathway

T2 - Estrogen Receptor-α, Progesterone Receptor, and Estrogen Receptor-β Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens

AU - Tan, Winston

AU - Boorjian, Stephen

AU - Advani, Pooja

AU - Farmer, Sara

AU - Lohse, Christine

AU - Cheville, John

AU - Kwon, Eugene D

AU - Leibovich, Bradley

PY - 2015/10/1

Y1 - 2015/10/1

N2 - The estrogen pathway has been implicated in bladder cancer growth and progression. We evaluated the expression and intensity of estrogen receptor (ER)-α, ER-β, and progesterone receptor in patients with urothelial cell carcinoma who were treated with cystectomy. Progesterone receptor expression was negative in all cases. ER-α expression was noted in 12 of 318 patients, and ER-β expression was noted in all patients. Marked ER-β intensity was associated with decreased lymph node metastasis, smaller tumor size, preoperative Bacillus Calmettee - Guérin, and less nonorgan-confined disease, suggesting a potential prognostic role of ER-β in urothelial cell carcinoma. Objective: Bladder cancer has the sixth highest incidence in the United States. Treatment of metastatic bladder cancer is difficult, and mortality is certain. There are certain pathways in cancer growth and progression that are important in bladder cancer development. Recently, the estrogen pathway has been found to be a potential target for therapy. Methods: We identified 410 patients treated with radical cystectomy for urothelial cell carcinoma between 1990 and 1994. We obtained representative paraffin-embedded tissue blocks for 336 (82.0%) of these cases and evaluated the expression and intensity of estrogen receptor (ER)-α, ER-β, and progesterone receptor by immunohistochemistry. Results: Among the 12 ER-α-positive cases, median tumor ER-α expression was 10% (range, 10%-50%). In contrast to ER-α, all cases were ER-β-positive. Median tumor ER-β expression was 90% (range, 20%-100%). Nearly all cases had ER-β expression of ≥ 90% (175 [55.9%] with 90% and 103 [32.9%] with 100%). However, the intensity of ER-β staining varied from focal to moderate to marked in 64 (20.5%), 167 (53.4%), and 82 (26.2%) cases, respectively. Progesterone receptor expression was noted to be negative in all cases. Conclusions: ER-β is highly expressed in bladder cancer. Prospective validation of these data might further elucidate the utility of ER-β as a marker for prognosis or possible target for therapy.

AB - The estrogen pathway has been implicated in bladder cancer growth and progression. We evaluated the expression and intensity of estrogen receptor (ER)-α, ER-β, and progesterone receptor in patients with urothelial cell carcinoma who were treated with cystectomy. Progesterone receptor expression was negative in all cases. ER-α expression was noted in 12 of 318 patients, and ER-β expression was noted in all patients. Marked ER-β intensity was associated with decreased lymph node metastasis, smaller tumor size, preoperative Bacillus Calmettee - Guérin, and less nonorgan-confined disease, suggesting a potential prognostic role of ER-β in urothelial cell carcinoma. Objective: Bladder cancer has the sixth highest incidence in the United States. Treatment of metastatic bladder cancer is difficult, and mortality is certain. There are certain pathways in cancer growth and progression that are important in bladder cancer development. Recently, the estrogen pathway has been found to be a potential target for therapy. Methods: We identified 410 patients treated with radical cystectomy for urothelial cell carcinoma between 1990 and 1994. We obtained representative paraffin-embedded tissue blocks for 336 (82.0%) of these cases and evaluated the expression and intensity of estrogen receptor (ER)-α, ER-β, and progesterone receptor by immunohistochemistry. Results: Among the 12 ER-α-positive cases, median tumor ER-α expression was 10% (range, 10%-50%). In contrast to ER-α, all cases were ER-β-positive. Median tumor ER-β expression was 90% (range, 20%-100%). Nearly all cases had ER-β expression of ≥ 90% (175 [55.9%] with 90% and 103 [32.9%] with 100%). However, the intensity of ER-β staining varied from focal to moderate to marked in 64 (20.5%), 167 (53.4%), and 82 (26.2%) cases, respectively. Progesterone receptor expression was noted to be negative in all cases. Conclusions: ER-β is highly expressed in bladder cancer. Prospective validation of these data might further elucidate the utility of ER-β as a marker for prognosis or possible target for therapy.

KW - Estrogen receptor

KW - Muscle-invasive bladder cancer

KW - Prognosis

KW - Urothelial cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84941599386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941599386&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2015.04.001

DO - 10.1016/j.clgc.2015.04.001

M3 - Article

C2 - 25981333

AN - SCOPUS:84941599386

VL - 13

SP - 476

EP - 484

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 5

ER -